
## Eric Nguyen-Khac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1759639/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390.	2.6	15
2	ABO blood group does not influence Childâ€Pugh A cirrhosis outcome: An observational studyÂfrom CIRRAL and ANRS CO12 CIRVIR cohorts. Liver International, 2022, 42, 1386-1400.	1.9	2
3	Complete endoscopic healing is associated with lower disability than partial endoscopic healing in Crohn's disease: A prospective multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101887.	0.7	4
4	Management of alcoholâ€related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver International, 2022, 42, 1330-1343.	1.9	10
5	Positive histologic margins is a risk factor of recurrence after ileocaecal resection in Crohn's disease. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101569.	0.7	5
6	Safety and efficacy of percutaneous transhepatic–endoscopic rendezvous procedure in a single session. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3534-3539.	1.3	2
7	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	1.1	4
8	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. JHEP Reports, 2021, 3, 100285.	2.6	4
9	Large-scale screening of lipase acid deficiency in at risk population. Clinica Chimica Acta, 2021, 519, 64-69.	0.5	7
10	Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. Liver International, 2020, 40, 1042-1051.	1.9	10
11	Type 2 refractory celiac disease on third-generation capsule endoscopy and enteroscopy: typical appearance of ulcerative jejunitis. Endoscopy, 2020, 52, E195-E197.	1.0	1
12	Personalized surveillance for hepatocellular carcinoma in cirrhosis– using machine learning adapted to HCV status. Journal of Hepatology, 2020, 73, 1434-1445.	1.8	52
13	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Journal of Hepatology, 2020, 73, 1046-1062.	1.8	79
14	Inflammatory bowel disease symptoms at the time of anal fistula lead to the diagnosis of Crohn's disease. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 968-972.	0.7	6
15	Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World Journal of Hepatology, 2020, 12, 1326-1340.	0.8	2
16	THU-142-Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program. Journal of Hepatology, 2019, 70, e224.	1.8	4
17	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. Radiology, 2019, 291, 801-808.	3.6	31
18	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 454-465.	3.7	36

ERIC NGUYEN-KHAC

#	Article	IF	CITATIONS
19	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
20	Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Digestive and Liver Disease, 2019, 51, 484-488.	0.4	11
21	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology, 2018, 68, 1245-1259.	3.6	33
22	Benefits of Laparoscopic Approach for Resection of Liver Tumors in Cirrhotic Patients. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2018, 28, 553-561.	0.5	8
23	Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. Oncotarget, 2018, 9, 16248-16262.	0.8	14
24	The epidemiology of Budd–Chiari syndrome in France. Digestive and Liver Disease, 2018, 50, 931-937.	0.4	32
25	Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. Journal of Hepatology, 2018, 69, 1274-1283.	1.8	86
26	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 614-625.	3.7	91
27	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney International, 2018, 94, 206-213.	2.6	18
28	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 2018, 378, 2171-2181.	13.9	383
29	Acute cholangitis complicating a chronic alveolar echinococcosis: an unusual therapeutic cholangioscopy. Endoscopy, 2018, 50, E214-E215.	1.0	0
30	Meckel's diverticulum on third-generation video capsule endoscopy: intradiverticular ulcer, ectopic gastric mucosa, and active bleeding. Endoscopy, 2018, 50, E205-E207.	1.0	4
31	Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver International, 2017, 37, 1314-1324.	1.9	68
32	High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. Archives of Virology, 2017, 162, 1913-1920.	0.9	2
33	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595
34	DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase. Antiviral Research, 2017, 146, 153-160.	1.9	7
35	Hemoglobin during ribavirinâ€based HCV therapy is closely related to circulating levels of DHEA. Journal of Medical Virology, 2017, 89, 1033-1039.	2.5	2
36	Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study. Digestive Diseases and Sciences, 2017, 62, 1571-1579.	1.1	48

ERIC NGUYEN-KHAC

#	Article	IF	CITATIONS
37	Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV–HCV genotype 1 coinfection. European Journal of Gastroenterology and Hepatology, 2016, 28, 486-487.	0.8	1
38	Management of colorectal cancer in patients with cirrhosis: A retrospective, case-matched study of short- and long-term outcomes. Digestive and Liver Disease, 2016, 48, 429-434.	0.4	16
39	Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. European Journal of Gastroenterology and Hepatology, 2016, 28, 876-881.	0.8	31
40	RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget, 2016, 7, 9832-9843.	0.8	12
41	Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget, 2016, 7, 32493-32503.	0.8	13
42	Patients treated with firstâ€generation HCV protease inhibitors exhibit high ribavirin concentrations. Journal of Clinical Pharmacology, 2015, 55, 517-524.	1.0	6
43	Which therapeutic option for hepatitis C virus genotype 1?. Scandinavian Journal of Gastroenterology, 2015, 50, 470-478.	0.6	3
44	Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. Journal of Hepatology, 2015, 62, 822-830.	1.8	156
45	DHEA and progesterone have a protective effect on ribavirin-induced hemolysis. Journal of Hepatology, 2014, 60, 897-898.	1.8	7
46	Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. Journal of Medical Virology, 2013, 85, 1191-1198.	2.5	2
47	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology, 2013, 58, 1742-1756.	3.6	87
48	Equal efficacy between the two types of peginterferon on HCV: A matter of relapse?. Antiviral Research, 2013, 98, 1-3.	1.9	7
49	The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. Therapeutic Drug Monitoring, 2013, 35, 791-795.	1.0	7
50	A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. International Journal of Hepatology, 2013, 2013, 1-11.	0.4	16
51	ls Stenting as "a Bridge to Surgery―an Oncologically Safe Strategy for the Management of Acute, Left-Sided, Malignant, Colonic Obstruction? A Comparative Study With a Propensity Score Analysis. Annals of Surgery, 2013, 258, 107-115.	2.1	240
52	Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. PLoS ONE, 2013, 8, e82918.	1.1	13
53	Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients. World Journal of Hepatology, 2013, 5, 104.	0.8	17
54	The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells. Antimicrobial Agents and Chemotherapy, 2012, 56, 903-908.	1.4	7

**ERIC NGUYEN-KHAC** 

#	Article	IF	CITATIONS
55	A New Tool to Study Ribavirin-Induced Haemolysis. Antiviral Therapy, 2012, 17, 1311-1317.	0.6	10
56	Glucocorticoids plus <i>N</i> -Acetylcysteine in Severe Alcoholic Hepatitis. New England Journal of Medicine, 2011, 365, 1781-1789.	13.9	335
57	Lack of association between tumour necrosis factor receptor types 1 and 2 gene polymorphism and severe acute alcoholic hepatitis. European Journal of Gastroenterology and Hepatology, 2010, 22, 794-800.	0.8	4
58	Ribavirin Monitoring in Chronic Hepatitis C Therapy: Anaemia versus Efficacy. Antiviral Therapy, 2010, 15, 687-695.	0.6	56
59	Noninvasive Diagnosis of Large Esophageal Varices by Fibroscan: Strong Influence of the Cirrhosis Etiology. Alcoholism: Clinical and Experimental Research, 2010, 34, 1146-1153.	1.4	45
60	BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma. Molecular Cancer Research, 2010, 8, 1116-1125.	1.5	50
61	Dynamic measurements of total hepatic blood flow with Phase Contrast MRI. European Journal of Radiology, 2010, 73, 119-124.	1.2	33
62	A Pitfall in the Diagnosis of Unresectable Liver Metastases: Multiple Bile Duct Hamartomas (von) Tj ETQq0 0 0 rgl	3T/Qverlo	ck <sub>5</sub> 10 Tf 50 4
63	Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study. Cancer Biology and Therapy, 2009, 8, 2033-2039.	1.5	12
64	Optimizing the treatment of chronic viral hepatitis C. Expert Review of Gastroenterology and Hepatology, 2009, 3, 607-613.	1.4	22
65	The â^'308 TNFα Gene Polymorphism in Severe Acute Alcoholic Hepatitis: Identification of a New Susceptibility Marker. Alcoholism: Clinical and Experimental Research, 2008, 32, 822-828.	1.4	14
66	Antioxidants plus corticosteroids in the treatment of severe acute alcoholic hepatitis: The question is still open. Journal of Hepatology, 2008, 49, 147-148.	1.8	2
67	Are ascitic electrolytes usable in cirrhotic patients? Correlation of sodium, potassium, chloride, urea, and creatinine concentrations in ascitic fluid and blood. European Journal of Internal Medicine, 2008, 19, 613-618.	1.0	11
68	Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?. European Journal of Internal Medicine, 2007, 18, 510-515.	1.0	4
69	Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology, 2007, 46, 1872-1882.	3.6	249
70	Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). European Journal of Gastroenterology and Hepatology, 2006, 18, 1321-1325.	0.8	61

71Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients by use of two reagent strips.0.8600.8